See more : Patient Access Solutions, Inc. (PASO) Income Statement Analysis – Financial Results
Complete financial analysis of Phathom Pharmaceuticals, Inc. (PHAT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phathom Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Satori Electric Co., Ltd. (7420.T) Income Statement Analysis – Financial Results
- Microsoft Corporation (MSFT.NE) Income Statement Analysis – Financial Results
- Groupon, Inc. (GRPN) Income Statement Analysis – Financial Results
- Adiuvo Investments S.A. (ADV.WA) Income Statement Analysis – Financial Results
- PT Perusahaan Gas Negara Tbk (PGAS.JK) Income Statement Analysis – Financial Results
Phathom Pharmaceuticals, Inc. (PHAT)
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 682.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 167.00K | 620.00K | 521.00K | 300.00K | 8.00K | 0.00 |
| Gross Profit | 515.00K | -620.00K | -521.00K | -300.00K | -8.00K | 0.00 |
| Gross Profit Ratio | 75.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.90M | 71.44M | 72.34M | 98.15M | 99.27M | 20.00K |
| General & Administrative | 0.00 | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.93M | 101.00M | 62.74M | 27.52M | 6.94M | 1.21M |
| Other Expenses | 0.00 | -110.00K | -2.06M | -8.00K | -49.56M | -50.00K |
| Operating Expenses | 167.83M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Cost & Expenses | 167.99M | 172.44M | 135.08M | 125.67M | 106.22M | 1.23M |
| Interest Income | 7.88M | 2.13M | 41.00K | 1.09M | 1.09M | 0.00 |
| Interest Expense | 41.97M | 27.31M | 6.79M | 4.58M | 4.18M | 13.00K |
| Depreciation & Amortization | 575.00K | 620.00K | 521.00K | 300.00K | 8.00K | 1.23M |
| EBITDA | -159.05M | -171.82M | -134.56M | -124.19M | -250.95M | -50.00K |
| EBITDA Ratio | -23,320.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -167.31M | -172.44M | -135.08M | -125.67M | -106.22M | -1.23M |
| Operating Income Ratio | -24,532.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -34.28M | -25.28M | -8.80M | -3.40M | -148.92M | -63.00K |
| Income Before Tax | -201.59M | -197.72M | -143.88M | -129.07M | -255.13M | -1.29M |
| Income Before Tax Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 25.28M | 4.21M | 4.25M | -45.39M | 13.00K |
| Net Income | -201.59M | -223.01M | -148.09M | -133.32M | -209.74M | -1.29M |
| Net Income Ratio | -29,558.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| EPS Diluted | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Weighted Avg Shares Out | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
| Weighted Avg Shares Out (Dil) | 51.29M | 39.12M | 37.00M | 33.23M | 24.73M | 8.58M |
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson -...
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago.
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter of 2024, and provided...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA...
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches,...
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate...
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly...
The 3 Best Healthcare Stocks to Buy in May 2024
Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to loss of $0.89 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports